LMBRD2

Across TCGA pan-cancer cohorts, LMBRD2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LMBRD2 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LMBRD2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LMBRD2 expression acts as an unfavorable survival marker.

HNSC, LUAD, and LSCC are the cancer types where LMBRD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.900	1.000	.018	9	view →
LUAD	DFS	Tertile	II,III,IV	0.201	0.811	.014	8	view →
LSCC	DFS	Tertile	II,III,IV	0.355	1.000	.006	7	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LMBRD2–HNSC (DFS)

Open the HNSC breakdown →